Indivior, a UK pharmaceutical company, is withdrawing Sublocade from the Australian market by the end of 2026. Sublocade is a long-acting injection of buprenorphine — an opioid medication — that patients receive once a month to treat opioid dependence. The drug is currently subsidised through Australia's Pharmaceutical Benefits Scheme (PBS) at a cost of $379.54 per injection, but that support will no longer matter once the product leaves.

The withdrawal cuts short a presence Indivior built starting in late 2019, when Sublocade rolled out here alongside launches in Canada and Europe. The drug was designed to solve a real problem in addiction treatment: daily tablets or films are easy to skip, trade away, or divert to others. A monthly injection removes that burden entirely and keeps the medication in the patient's hands only when they need it — a distinction with measurable clinical weight.

For patients in opioid agonist therapy — a structured medical treatment for dependence — Sublocade offered something sublingual buprenorphine could not easily provide: freedom from daily attendance at clinics or pharmacies, and genuine protection against the diversion of medication to the black market. That mattered operationally. Addiction services could treat more patients without the daily supervision overhead that made traditional buprenorphine so resource-intensive.

Why Indivior Is Leaving

The Australian exit sits within a larger financial unravelling at Indivior. The company has endured years of generic litigation, government scrutiny in the United States, and revenue decline. In September 2020, it announced plans to cut up to $70 million in costs through job reductions and supply chain restructuring — a signal of how severely the prior decade had squeezed its finances. The boardroom itself has been unstable: the finance chief stepped down as a director in December 2024, part of a broader restructuring that left uncertainty about the company's strategy outside the United States.

Sublocade was always meant to be Indivior's lifeline — the product designed to offset losses as its main oral Suboxone film patent expired. The company once positioned it as a potential billion-dollar drug. That bet hinged on capturing Australia, Canada, and Europe at meaningful scale. The decision to exit Australia by year-end tells us plainly: the commercial return here fell short of what the company needed to justify staying, even with the PBS subsidy in place.

What Happens to Patients Now

The practical fallout lands squarely on patients with few good alternatives. Sublingual buprenorphine-naloxone remains available, as does methadone through opioid treatment programs. But neither replicates the pharmacokinetic advantage — the way the body absorbs and processes the drug — or the adherence profile of a monthly depot. Patients who have stabilised on Sublocade, particularly those with histories of poor adherence to daily dosing or for whom clinic attendance is logistically difficult, now face a forced transition that carries genuine clinical risk.

Brixia's Buvidal — a weekly or monthly buprenorphine injection also listed on the PBS — offers a partial clinical substitute, though switching medications always carries some uncertainty. Clinicians will need to manage each transition individually, and opioid services will need to plan for the timeline as Indivior draws down stock.

A Broader Question

This withdrawal raises a structural issue worth flagging for Australia's addiction medicine sector. The Section 100 Highly Specialised Drugs pathway on the PBS is meant to secure access to niche medications. Sublocade's listing did that in principle. But Indivior's exit shows that regulatory approval is not the same as commercial viability. When a product serves a narrow patient population, offers limited price room under PBS negotiation, and the manufacturer faces financial stress, market withdrawal is always a latent risk. Australia's addiction services now have a concrete recent example of that risk — and a reason to build supply security planning into their advocacy and operational design.